At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hydroxychloroquine for Outpatients With Confirmed COVID-19
In Brief
A Phase 2 clinical trial evaluating Hydroxychloroquine and Placebo oral tablet for Coronavirus Infection and 2 related conditions. Completed, enrolled 368 participants across 1 site.
Detailed Summary
A novel coronavirus, SARS-CoV-2, is responsible for a rapidly spreading pandemic that has reached 160 countries, infecting over 500,000 individuals and killing more than 24,000 people. SARS-CoV-2 causes an acute and potentially lethal respiratory illness, known as COVID-19, that is threatening to overwhelm health care systems due to a dramatic surge in hospitalized and critically ill patients. Patients hospitalized with COVID-19 typically have been symptomatic for 5-7 days prior to admission, indicating that there is a window during which an effective intervention could significantly alter the course of illness, lessen disease spread, and alleviate the stress on hospital resources. There is no known treatment for COVID-19, though in vitro and one poorly controlled study have identified a potential antiviral activity for HCQ. The rationale for this clinical trial is to measure the efficacy and safety of hydroxychloroquine for reducing viral load and shedding in adult outpatients with confirmed COVID-19.
Study Details
Timeline
Interventions
HCQ 400mg po BID x 1 day, then 200mg po BID x 4 days
Placebo to be taken on the same schedule as HCQ.